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Abstract Combination of decreased energy expenditure
andincreasedfoodintakeresultsinfataccumulationeitherin
the abdominal site (upper body obesity, UBO) or on the hips
(lowerbodyobesity,LBO).Inthisstudy,weusedmicroarray
gene expression proﬁling of adipose tissue biopsies to
investigate the effect of body fat distribution on the physi-
ological response to two dietary fat interventions. Mildly
obese UBO and LBO male subjects (n = 12, waist-to-hip
ratio range 0.93–1.12) were subjected to consumption of
diets containing predominantly either long-chain fatty acids
(PUFA) or medium-chain fatty acids (MCT). The results
revealed (1) a large variation in transcription response to
MCT and PUFA diets between UBO and LBO subjects, (2)
higher sensitivity of UBO subjects to MCT/PUFA dietary
intervention and (3) the upregulation of immune and apop-
totic pathways and downregulation of metabolic pathways
(oxidative, lipid, carbohydrate and amino acid metabolism)
in UBO subjects when consuming MCT compared with
PUFA diet. In conclusion, we report that despite the rec-
ommendation of MCT-based diet for improving obesity
phenotype, this diet may have adverse effect on inﬂamma-
tory and metabolic status of UBO subjects. The body fat
distributionis,therefore, animportant parameter toconsider
when providing personalized dietary recommendation.
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Introduction
The principal causes of the increasing obesity problem
worldwide are sedentary lifestyles and an increased intake
of high-fat, energy-dense diets. Combination of decreased
energy expenditure and increased energy or food intake
results in fat accumulation either in the abdominal site
(upper body obesity, UBO) or on the hips (lower body
obesity, LBO), also known as the apple- and pear-shape
generalization. Handling of the consumed fatty acids is
hypothesized to be different in men with UBO and LBO
because of their fat disposition and the routing of the
different fatty acids. Upper body obesity also seems to
be related to increased metabolic risk [7].
It has been shown that the chain length of dietary fatty
acids affects fat absorption, fat metabolism and hepatic
gene expression proﬁles [4, 11, 13]. During the consump-
tion of dietary fats, the ﬁrst pass of the fatty acids differs:
the long-chain fatty acids (PUFA) will be absorbed by the
chylomicrons via the lymph and transported through the
body to the periphery and the medium-chain fatty acids
(MCT) will directly be transported as free fatty acids via
the portal vein to the liver [3, 8]. As a result, PUFA might
be disposed to the periphery (organs, muscles or subcuta-
neous fat) and MCT might easily be disposed centrally.
Owing to their rapid breakdown and routing directly to the
liver instead of being stored, diet rich in MCT has been
advised to people suffering from obesity problems [10, 14].
Inthisstudy,we investigated howadifference inbodyfat
distributionaffectsthe physiologicalresponsetotwodietary
fat interventions, namely consumption of a spread contain-
ing predominantly PUFA and a spread containing predom-
inantly MCT. We analyzed by microarray gene expression
proﬁling the response of subcutaneous adipose tissue from
upper body obese males and LBO males to these two
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physiological effects of dietary interventions are dependent
on body fat distribution. In addition, this study shows that
consumption of MCT-rich diet may have adverse effects for
upper body obese males, due to the increased inﬂammation
and decreased energy metabolism in adipose tissue.
Methods and materials
Study design and subjects
The study was conducted at TNO Quality of Life, where
subjects were recruited from a pool of volunteers. After
being informed about the study, both verbally and in writ-
ing, each subject signed the informed consent form. Twelve
healthy male subjects aged between 30 and 60 years and
with body mass index (BMI) between 27 and 35 kg/m
2
were included in the study. Subjects were selected so that
range of waist-hip ratio (WHR) was as high as possible, in
the selected group WHR ranged from 0.93 to 1.12. Subjects
with WHR\1( n = 7) were considered LBO and subjects
with WHR[1( n = 5) upper body obese (UBO) [1].
The study was approved by the Medical Ethics Com-
mittee ofTilburg (METOPP)(18April2007)andconducted
according to the current assembly (52nd) of the Declaration
of Helsinki (Edinburgh, Scotland, October 2000) and the
ICH Guidelines for Good Clinical Practice (ICH Topic E6,
adopted 01-05-1996 and implemented 17-01-1997). The
study was designed as a randomized, double-blind, cross-
overtrialandtwotreatmentsweresuppliedfor3 weekswith
a wash-out period of 6 weeks in-between. The two dietary
interventions consisted of consumption of a spread con-
taining predominantly PUFA (71% long-chain fatty acids
(mainly C18:2), 28% C16:0 and 1% fatty acids shorter than
C16)andconsumptionofaspreadcontainingpredominantly
MCT (65% C8:0 and C10:0, 29% C16:0 and 6% fatty acids
longerthanC18).Inboththespreads,asimilarpercentageof
palmiticacid(C16:0:28–29%)ispresent,necessarytomake
a margarine spreadable.
The treatments were given in random order. Randomi-
zation was restricted for age, BMI and WHR. Each day,
subjects consumed 60 g of the spread for 2.5 weeks; during
the start of the intervention period subjects only consumed
half the amount (so 30 g of test spread daily) to become
habituated to the unusual fatty acids. The test spread
replaced their normal spread and oil use. Two portions of
30 g of spread were consumed with each main meal; por-
tions of 15 g were provided at the beginning of the inter-
vention period. With the test spread provided, about 50%
of the daily fat intake was of experimental origin. During
the complete study period (84 days), no changes were seen
in body weight or waist and hip circumferences. Also, the
6 weeks wash-out in-between both test periods did not
affect these main characteristics of the study population.
Adipose tissue biopsies were taken at the end of the 3-
week intervention.
Adipose tissue biopsies
On days 21 and 63, the last day of each supplementation
period, biopsies of the subcutaneous fat tissue of the
abdomen were taken as follows. The skin was disinfected
with alcohol (70%) and after local anesthesia with lido-
caine a fat biopsy was taken by needle aspiration. Part of
the fat suspension was immediately frozen in liquid nitro-
gen and stored at –80C for RNA isolation. Adipose tissue
biopsies were not available from 1 subject, therefore, 11
subjects were included in the microarray analysis.
RNA isolation, labeling and hybridization
RNA was isolated using RNA-Bee (Campro Scientiﬁc,
Veenendaal, The Netherlands) and glass beads according to
the manufacturer’s instructions. The integrity of RNA
obtained was examined by Agilent Lab-on-a-chip tech-
nology using the RNA 6000 Nano LabChip kit and a
Bioanalyzer 2100 (both Agilent Technologies, Amstelveen,
The Netherlands).
The isolated RNA samples were sent to ServiceXS BV
(Leiden, The Netherlands) where they were processed
according to Affymetrix protocols. Brieﬂy, RNA concen-
tration was determined by absorbence at 260 nm, and
quality and integrity was veriﬁed using the Agilent 2100
Bioanalyzer (Agilent Technologies). Next, 2 lg of high
quality total RNA was used with the Affymetrix Eukary-
otic One-Cycle Target Labeling and Control reagents to
generate biotin-labeled antisense cRNA. The quality of the
cRNA was checked using the Agilent 2100 bioanalyzer.
The labeled cRNA was hybridized to the NuGO Affyme-
trix Human Genechip NuGO_Hs1a520180 (custom designed
by the European Nutrigenomics Organisation NuGO, con-
sistingof23,941probesetsincluding71controlprobesets,for
details see http://blog.bigcat.unimaas.nl/*martijn/NuGO/).
Absolute gene expression values were calculated from the
scanned array using the Affymetrix GCOS software. In total,
study included 22 microarray hybridizations (two treatments
of 11 subjects). The study design including one microarray
per subject for each treatment was chosen to maximize the
number of biological replicates (6 LBO and 5 UBO subjects)
and, thus, power to detect the expression differences.
Data analysis
Quality control and normalization of microarray data was
performed using R/BioConductor packages through the
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Raw signal intensities were normalized using the GCRMA
algorithm. The custom CDF ﬁle for NuGO_Hs1a520180
(based on Entrez Gene, version 10.0.0; available via
http://nugo-r.bioinformatics.nl/NuGO_R.html) was used to
re-annotate the probes to new probesets, remove poor quality
probesandderiveunique signalvaluesfor differentprobesets
representing the same gene. This resulted in gene expression
values for 16,242 genes with unique identiﬁers. The gene
expression was required tohave a value above 10 in atleast 1
of 22 samples, resulting in a set of 9,716 genes considered as
expressedinadiposetissue.Principalcomponentanalysisand
analysis of overrepresented Gene Ontology ‘‘Biological pro-
cess’’ categories were performed using GeneSpring GX 7.3.1
software (Agilent). A paired t test for treatment effect in
all subjects and the UBO and LBO subgroups was per-
formed in BRB ArrayTools (software for microarray data
analysis developed by Dr. Richard Simon and Amy Peng
Lam, http://linus.nci.nih.gov/BRB-ArrayTools.html), using
p-valueof0.01asathresholdforsigniﬁcance.Theper-subject
analysisofover-orunder-representedpathwaysandgenesets
upon consuming MCT versus PUFA spread was performed
using T-proﬁler [2]. As input values, log2 ratios of all 9,716
genes were used. Gene ontology (GO, www.geneontology.
org), curated gene sets and motif gene sets (Molecular
Signatures Database, http://www.broad.mit.edu/gsea/msigdb/
index.jsp) and Kyoto Encyclopedia of Genes and Genomes
(KEGG, http://www.genome.jp/kegg/) pathway collections
were used as source of queried gene sets. Pathways were
considered signiﬁcant if E-value (Bonferroni corrected)
was smaller than 0.05. T-values resulting from T-proﬁler
analysis were hierarchicaly clustered (Pearson correlation
(uncentered), complete linkage) and visualized by Hier-
archicalClusteringViewer and HeatmapViewer modules
within the GenePattern analysis suite [5, 6, 12]. The corre-
lation between WHR and gene expression was analysed in
SASEnterpriseguide4.1(SASInstituteInc.,Cary,USA).A
Pearson correlation coefﬁcient higher than 0.7 or lower then
–0.7, associated with p-value smaller than 0.016 was usedas
threshold for signiﬁcance. The gene expression data will be
made available through ArrayExpress, a public repository
for microarray data (www.ebi.ac.uk/arrayexpress/).
Results
Mildly obese male subjects with WHR ranging from 0.93
to 1.12 were submitted to MCT- and PUFA-based dietary
interventions and the RNA samples obtained from their fat
biopsies were hybridized to microarrays (Methods and
Materials). Subjects with WHR\1 were considered LBO
and those with WHR [1 upper body obese (UBO)
(Table 1).
After preprocessing of the microarray data, normalized
expression values were obtained for 9,716 genes expressed
in subcutaneous adipose tissue. The global relations among
the gene expression signatures of subjects fed two diets
were assessed by principal component analysis (PCA)
(Fig. 1). This reveals a large inter-subject variation in
the transcription response to MCT and PUFA dietary
interventions. Moreover, the division of subjects to an
UBO and LBO group explains more variance in gene
Table 1 Overview of subject’s identiﬁcation numbers, waist-to-hip
ratios (WHR, sorted from lowest to highest) and body fat distribution
grouping (either UBO or LBO)
Subject WHR Group
S9 0.934 LBO
S13 0.935 LBO
S4 0.971 LBO
S11 0.974 LBO
S7 0.986 LBO
S8 0.990 LBO
S2 1.000 UBO
S5 1.023 UBO
S3 1.030 UBO
S10 1.036 UBO
S1 1.122 UBO
PC 1 (19%)
PC 2 (11%)
PC 3 (10%)
UBO (MCT)
UBO (PUFA)
LBO (PUFA)
LBO (MCT)
Fig. 1 Principal component analysis of the adipose tissue gene
expression. Principal component analysis of the adipose tissue gene
expression in 11 subjects, each in two dietary conditions (ﬁve UBO
and six LBO, each after consumption of both MCT and PUFA
spread). There is a large inter-subject variation in gene expression
response to MCT and PUFA treatments. The distinction between
UBO and LBO groups explains most variance observed in the data
(red versus green dots)
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123expression than the grouping of subjects according to a
diet. This shows that the body fat distribution represents the
principal determinant of a diet effect on the adipose tissue
gene expression. The observed relevance of body fat dis-
tribution for the effects of dietary fat interventions under-
scores different physiological characteristics of UBO and
LBO subjects and suggests that this phenotypic property
should be considered when assessing MCT and PUFA diet
effects.
The distinct transcriptional response of UBO and LBO
subjects was supported by statistical analysis of differen-
tially expressed genes between MCT- and PUFA-based
dietary interventions. To investigate the overall effects of
the MCT and PUFA diets, a paired (per subject) t test
comparing two interventions (MCT vs. PUFA) was per-
formed in (1) all subjects and (2) separately in UBO and
LBO groups. Applying the statistical cutoff of p-value
\0.01, 179 genes were identiﬁed as differentially expres-
sed among all subjects, whereas 239 and 73 genes were
identiﬁed as differentially expressed in UBO and LBO
groups, respectively. Despite the decreased sample number
when analysis was performed separately for UBO and LBO
groups, we were able to identify a larger number of dif-
ferentially expressed genes in the UBO group than when all
subjects were analysed. This conﬁrms the large heteroge-
neity of inter-subject responses to two dietary interventions
observed by PCA and the dependence of this response on
the subject’s body fat distribution. In addition, three times
larger number of differentially expressed genes in UBO
compared to LBO group shows that UBO subjects are more
sensitive than LBO subjects to MCT versus PUFA dietary
intervention.
The effects of body fat distribution on the changes in
biological processes upon consuming MCT and PUFA
spread were analyzed by T-proﬁler [2]. This method
enables subject-speciﬁc identiﬁcation of biological pro-
cesses that are signiﬁcantly induced or repressed by dietary
interventions. To increase the robustness of the analysis,
four collections of gene sets associated with various bio-
logical processes were used for analysis as described in
‘‘Methods and Materials’’ section. The resulting T-scores
represent relative up- and down-regulation of pathways in
MCT versus PUFA comparison. In total, 547 pathways
were identiﬁed as signiﬁcantly regulated in at least one of
11 subjects (Fig. 2). The T-scores were hierarchically
clustered, resulting in aggregation of similarly regulated
pathways. In addition, hierarchical clustering of subjects
based on their pathway proﬁles (Fig. 2a) showed correla-
tion of subject’s responses to MCT compared to PUFA. In
agreement with PCA and statistical analysis, subjects with
tendency to LBO (WHR 0.93–0.97, subjects S9, S13, S4
and S11) reacted differently to the dietary fat intervention
than the subjects with tendency to UBO (WHR 0.99–1.12,
subjects S7, S8, S3, S5, S10, S2 and S1). Focusing on
particular sub-clusters revealed that the subjects with
higher WHR have higher expression of the apoptotic,
inﬂammatory and immune response pathways (Fig. 2b) and
lower expression of mitochondrial, oxidative, fatty acid
and amino acid metabolic pathways (Fig. 2c) than the
subjects with lower WHR when they are consuming MCT
compared to PUFA spread. These ﬁndings underscore the
impact of the body fat distribution on the important factors
in obesity-associated disorders, such as inﬂammation and
energy metabolism of adipose tissue. Observed differential
regulation of these processes by MCT and PUFA diets in
UBO and LBO subjects imply that harmonization of a diet
composition with the body fat distribution proﬁle is
necessary for improving subject’s obesity status by dietary
intervention.
The dependence of biological effects of two diets on
the subject’s body fat distribution was further investigated
by correlation of individual gene expression changes
(log2(MCT/PUFA)) to the WHR values. Applying the
signiﬁcance threshold of (r) [0.7 or \–0.7 (Pearson cor-
relation) and p-value \0.016, 44 genes were found to be
positively correlated and 165 negatively correlated with
WHR (data not shown). The correlation of gene expression
with WHR identiﬁes genes which expression in response to
MCT versus PUFA dietary intervention can be predicted by
subject’s body fat distribution. Positive correlation implies
that in MCT/PUFA comparison, the gene will be upregu-
lated in UBO subjects and downregulated in LBO subjects.
Conversely, negative correlation means that in the MCT/
PUFA comparison, given gene will be downregulated in
UBO but upregulated in LBO subjects. Consistent with the
pathway analysis results obtained by T-proﬁler, biological
functions of genes with signiﬁcant positive correlation
between log2(MCT/PUFA) ratio and WHR are involved in
immune response and mitochondrial apoptosis, while genes
with negative correlation of log2(MCT/PUFA) ratio and
WHR are implicated in metabolic and oxidative processes
(Fig. 3a, b). As an increased inﬂammation and decreased
energy metabolism in adipose tissue are considered to have
negative effect on obesity-associated disorders, our results
suggest that consumption of MCT-instead of PUFA-rich
diet may have adverse effects in UBO subjects, while it
may be beneﬁcial to LBO subjects.
Examples of genes that have MCT versus PUFA
expression ratio signiﬁcantly correlated to subject’s
WHR values are MICB (MHC class I polypeptide-related
sequence B) (positive correlation) and ADIPOQ (adipo-
nectin) (negative correlation). MICB is a stress-induced
protein involved in inﬂammatory/immune response and
low adiponectin expression represents known marker of
obesity-associated disorders. MICB MCT/PUFA expres-
sion ratio increases in subjects with higher WHR (UBO)
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123(Fig. 4a), while ADIPOQ MCT/PUFA expression ratio
decreases in subjects with higher WHR (Fig. 4b). There-
fore, the expression changes of these two genes reﬂect an
increased inﬂammation of adipose tissue coupled with
decreased expression of adiponectin in UBO subjects when
MCT diet is consumed instead of the PUFA diet. Again,
this suggests that MCT-rich diet may aggravate the obes-
ity-related complications in subjects with high WHR
(tendency to UBO). In contrast, this diet may have favor-
able effect for LBO subjects, as inﬂammation decreases
and adiponectin increases in these subjects when they
consume MCT instead of PUFA diet.
Discussion
Long and medium-chain fatty acids have different meta-
bolic routing upon consumption: while long-chain fatty
acids are considered to be disposed to the periphery,
medium-chain fatty acids are rather disposed centrally.
In addition, medium-chain fatty acids are more rapidly
oxidized, increase energy expenditure after short-term
feeding and attenuate weight gain after long-term feeding
compared to long-chain fatty acids [10]. These differences
in metabolic handling form a basis for a belief that con-
sumption of MCT (as opposed to PUFA) may be beneﬁcial
for improving obesity-associated disorders.
In this study, we investigated the effect of body fat
distribution on the physiological response to dietary fat
interventions based on MCT and long-chain fatty acids
(PUFA). The microarray gene expression proﬁling of the
subcutaneous adipose tissue revealed that (1) there is a
large variation in the transcription response to MCT and
PUFA diets between UBO and LBO subjects, (2) UBO
subjects are more sensitive to MCT versus PUFA dietary
intervention than the LBO subjects and (3) the regulation
of immune and apoptotic response and metabolic activity
(including oxidative, lipid, carbohydrate and amino acid
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123metabolism) in response to MCT versus PUFA dietary
intervention can be predicted by subject’s body fat distri-
bution: immune and apoptotic response increase, while
metabolic activity decreases with increasing WHR.
These results demonstrate that the beneﬁt of consump-
tion of MCT-rich diet on obesity disorders strongly
depends on body fat distribution. Although this diet may
have positive effects for LBO subjects, increased inﬂam-
mation and decreased energy metabolism suggest that
MCT-rich diet has adverse effect on obesity-related com-
plications of UBO subjects. The origin of these negative
effects may be associated with hepatic fatty acid overload
in UBO subjects. Since the UBO phenotype is usually
associated with non-alcoholic fatty liver disease (NAFLD),
transport of MCT directly to the liver by the portal vein
may result in excessive hepatic fatty acid burden. This in
turn would cause negative effects on obesity disorders on
the systems level and provoke adverse changes that we
detect in adipose tissue. The proposed mechanism is not
plausible in LBO subjects because the particular risk of
developing hepatic steatosis is speciﬁc to central obesity
(UBO) [9].
The results obtained in this study highlight the impor-
tance of the personalized approach to understanding of a
complex relationship between diet and physiology. The
body fat distribution emerges as an important parameter to
consider when assessing effects of long and medium chain
dietary fats. Employment of a means to predict subject-
speciﬁc effects of dietary interventions, such as gene
expression signatures and biomarker levels, may be an
essential component necessary to provide an appropriate
dietary recommendation.
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